公开(公告)号：US12036247B2

公开(公告)日：2024-07-16

申请号：US16604675

申请日：2018-04-12

申请人： EpicentRx, Inc.

发明人： Tony R. Reid ,  Christopher Larson ,  Bryan T. Oronsky

IPC分类号： A61P35/00 ,  A61K35/74 ,  A61K35/768 ,  A61K48/00 ,  C07K14/54 ,  C12N9/64 ,  C12N15/86 ,  C12N15/861

CPC分类号： A61K35/74 ,  A61K35/768 ,  A61K48/00 ,  A61P35/00 ,  C12N9/6454 ,  C12N15/86 ,  C12N15/861 ,  C07K2319/50 ,  C12N2710/10343 ,  C12Y304/21075

摘要： The invention relates to a recombinant adenovirus comprising two or more therapeutic transgenes, e.g., two components of a heterodimeric cytokine, separated by a cleavable linker.

公开(公告)号：US20210178050A1

公开(公告)日：2021-06-17

申请号：US17119423

申请日：2020-12-11

申请人： EpicentRx, Inc.

发明人： Bryan T. Oronsky ,  Scott Caroen

IPC分类号： A61M1/36 ,  A61M1/38

摘要： Devices, systems, and methods for medication infusion are described herein. In some embodiments, a system includes a patient access subassembly, a first fluid reservoir, a second fluid reservoir, and an assembly. The assembly can have a first configuration in which the patient access subassembly is in fluid communication with the first fluid reservoir via a first tube, a second configuration in which the first fluid reservoir is in fluid communication with the second fluid reservoir, and a third configuration in which the first fluid reservoir is in fluid communication with the patient access subassembly via a second tube, the first fluid reservoir fluidically isolated from the first tube in the third configuration.

公开(公告)号：US10342778B1

公开(公告)日：2019-07-09

申请号：US15298735

申请日：2016-10-20

申请人： EpicentRx, Inc.

发明人： Bryan T. Oronsky ,  Jan Scicinski

IPC分类号： A61N5/10 ,  A61K31/397 ,  A61K9/00 ,  A61K31/495

摘要： The invention provides therapeutic methods and kits for treating brain metastases using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and optionally an additional anti-cancer agent.

公开(公告)号：US20240122977A1

公开(公告)日：2024-04-18

申请号：US18221060

申请日：2023-07-12

申请人： EpicentRx, Inc.

发明人： Bryan T. ORONSKY

IPC分类号： A61K35/16 ,  A61K31/282 ,  A61K31/337 ,  A61K31/407 ,  A61K31/4745 ,  A61K31/675 ,  A61K31/704 ,  A61K31/7042 ,  A61K35/15 ,  A61K47/46 ,  A61P35/00

CPC分类号： A61K35/16 ,  A61K31/282 ,  A61K31/337 ,  A61K31/407 ,  A61K31/4745 ,  A61K31/675 ,  A61K31/704 ,  A61K31/7042 ,  A61K35/15 ,  A61K47/46 ,  A61P35/00 ,  A61K9/0019

摘要： The invention provides compositions and methods for administering a therapeutic agent to a patient, such as pharmaceutical compositions containing a blood product and a therapeutic agent selected from an anthracycline anti-cancer agent (e.g., doxorubicin), a topoisomerase inhibitor, an oxazaphosphinanyl anti-cancer agent, a nitro-aryl anti-cancer agent, a thiol-reactive functional-group agent, a nitric oxide modulator, a platinum-based antineoplastic compound, acrylamide, acrylonitrile, bis(4-fluorobenzyl)trisulfide, a cardiac glycoside, an anti-mitotic agent (e.g., paclitaxel), a nucleoside analog, an EGFR inhibitor, or an anti-microbial agent.

公开(公告)号：US11834492B2

公开(公告)日：2023-12-05

申请号：US16651079

申请日：2018-09-27

申请人： EpicentRx, Inc.

发明人： Christopher Larson ,  Tony R. Reid ,  Bryan T. Oronsky

IPC分类号： C07K14/715 ,  A61P35/00 ,  C07K14/54 ,  C12N15/62 ,  A61K38/00

CPC分类号： C07K14/7155 ,  A61P35/00 ,  C07K14/5428 ,  C12N15/62 ,  A61K38/00 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/50

摘要： Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

公开(公告)号：US20230233524A1

公开(公告)日：2023-07-27

申请号：US18083922

申请日：2022-12-19

申请人： EpicentRx, Inc.

发明人： Bryan T. ORONSKY ,  Jan SCICINSKI ,  Scott CAROEN

IPC分类号： A61K31/397 ,  A61P35/02 ,  A61P35/00 ,  A61K9/00 ,  A61K31/194 ,  A61K31/727 ,  A61K35/14 ,  A61K47/10 ,  A61K47/18

CPC分类号： A61K31/397 ,  A61P35/02 ,  A61P35/00 ,  A61K9/0019 ,  A61K31/194 ,  A61K31/727 ,  A61K35/14 ,  A61K47/10 ,  A61K47/18 ,  A61K47/46

摘要： The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), including formulations containing, autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous infusion without any significant pain at the site of infusion.

公开(公告)号：US11701351B2

公开(公告)日：2023-07-18

申请号：US17223422

申请日：2021-04-06

申请人： EpicentRx, Inc.

发明人： Bryan T. Oronsky ,  Jan Scicinski

IPC分类号： A61K31/495 ,  A61K31/397 ,  A61K9/00 ,  A61K31/4745 ,  A61N5/10

CPC分类号： A61K31/495 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/397 ,  A61K31/4745 ,  A61N5/10 ,  A61K31/495 ,  A61K2300/00 ,  A61K31/397 ,  A61K2300/00

摘要： The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.

公开(公告)号：US11660286B2

公开(公告)日：2023-05-30

申请号：US16284035

申请日：2019-02-25

申请人： EpicentRx, Inc.

发明人： Bryan T. Oronsky ,  Jan Scicinski ,  Susan Knox ,  William Fitch ,  Frans A. Kuypers ,  Marcel Fens ,  Sandra Larkin ,  Pedro Cabrales ,  Chad Brouse

IPC分类号： A61K31/397 ,  A61K33/00 ,  A61K45/06 ,  A61K31/22 ,  A61K31/12 ,  A61K31/255 ,  A61K31/445 ,  A61K31/215 ,  A61K31/16 ,  A61K31/198 ,  A61K31/40 ,  A61K47/64 ,  A01N1/02 ,  A61K35/14 ,  A61K35/16 ,  A61K35/18 ,  A61K38/17 ,  A61N5/10

CPC分类号： A61K31/397 ,  A01N1/0226 ,  A61K31/12 ,  A61K31/16 ,  A61K31/198 ,  A61K31/215 ,  A61K31/22 ,  A61K31/255 ,  A61K31/40 ,  A61K31/445 ,  A61K33/00 ,  A61K35/14 ,  A61K35/16 ,  A61K35/18 ,  A61K38/1709 ,  A61K45/06 ,  A61K47/6445 ,  A61N5/10 ,  Y02A50/30 ,  A61K33/00 ,  A61K2300/00 ,  A61K31/397 ,  A61K2300/00 ,  A61K31/40 ,  A61K2300/00 ,  A61K31/445 ,  A61K2300/00 ,  A61K31/12 ,  A61K2300/00 ,  A61K31/22 ,  A61K2300/00 ,  A61K31/215 ,  A61K2300/00 ,  A61K31/255 ,  A61K2300/00 ,  A61K31/16 ,  A61K2300/00 ,  A61K31/198 ,  A61K2300/00

摘要： The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.

公开(公告)号：US20210244870A1

公开(公告)日：2021-08-12

申请号：US17251552

申请日：2019-06-11

申请人： EpicentRx, Inc.

发明人： Bryan T. Oronsky ,  Scott Caroen ,  Tony R. Reid ,  Corey Carter ,  Jeannie Williams

IPC分类号： A61M1/34 ,  A61M1/38 ,  A61M1/36

摘要： Devices, systems, and methods for medication infusion are described herein. In some embodiments, a system includes a patient access subassembly, a first fluid reservoir, a second fluid reservoir, and an assembly. The assembly can have a first configuration in which the patient access subassembly is in fluid communication with the first fluid reservoir via a first tube, a second configuration in which the first fluid reservoir is in fluid communication with the second fluid reservoir, and a third configuration in which the first fluid reservoir is in fluid communication with the patient access subassembly via a second tube, the first fluid reservoir fluidically isolated from the first tube in the third configuration.

公开(公告)号：US20210015878A1

公开(公告)日：2021-01-21

申请号：US17042822

申请日：2019-03-28

申请人： EpicentRx, Inc.

发明人： Christopher LARSON ,  Bryan T. ORONSKY ,  Tony R. REID

IPC分类号： A61K35/761 ,  A61K38/16 ,  C12N15/10 ,  C12N15/861

摘要： The invention provides for a recombinant adenoviral vector comprising a recombinant oncolytic adenovirus which has: (1) a modified transcription regulatory sequence wherein the adenoviral vector is transcriptionally active in cancer cells and/or hyperproliferative cells and transcriptionally attenuated in normal cells, and (2) a transgene encoding one or more cancer antigens that are specific to a subject. The invention further provides a method of producing said recombinant adenoviral vector. The recombinant oncolytic adenoviral vector described above is used in methods of stimulating a heightened immune response against a cancer antigen in a subject or a method of treating cancer in a subject.